Form 4: Iovance Biotherapeutics Executive Raj K. Puri Reports Stock Transactions
SEC Form 4 Filing
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 14, 2025, Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, had 8,334 restricted stock units (RSUs) vest.
- The company withheld 2,509 shares to satisfy tax obligations at a price of $3.59 per share.
- Following these transactions, Puri directly owns 201,252 shares of Iovance common stock.
- The reported transactions do not represent an open market sale of securities.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. This provides transparency to the market regarding insider activity.
Comparison to Industry Standards
- Similar to other biotechnology companies, Iovance uses restricted stock units (RSUs) as part of its compensation package for executives.
- The vesting schedules and tax withholding practices are generally consistent with industry norms for equity compensation.
Key Dates
| Date | Description |
|---|---|
| 03/14/2022 | Date of grant for the reported RSUs |
| 03/14/2025 | Date of RSU vesting and tax withholding |
| 03/18/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.